A recent study led by MHRP researchers showed elevated B cell immune interactions with the envelope glycoprotein (Env) on the surface of HIV during the first month of HIV infection predict the development of broadly neutralizing antibodies (bNAbs) years later.
A recent preclinical study by U.S. Military HIV Research Program (MHRP) researchers showed that an experimental therapy combining a TLR7 agonist and two broadly neutralizing antibodies delayed viral rebound in SHIV-infected macaques after antiretroviral therapy (ART) interruption.
MHRP researchers recently published findings from a study comparing HIV gene and genome sequence analyses to help inform strategies to best estimate the timing of HIV infection.
In Kenya, the HIV epidemic among adolescents and young people between the ages of 10 and 24 is characterized by relatively high HIV incidence and sub-optimal treatment outcomes, including a high loss to follow-up, low adherence to treatment and low viral suppression.
